A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

Part of paid clinical trials in Los Angeles, California.

Sponsor
Ipsen
Study ID
NCT06850038
Status
Recruiting

Conditions

  • Alagille Syndrome

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

This study will collect information from patients with Alagille syndrome (ALGS) as they use odevixibat (Bylvay) in their daily lives. Odevixibat is a medicine that helps patients with ALGS, a rare disease that harms their liver and causes itching. The main aim of this study is to observe the long-term, everyday effectiveness and safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.

Key Dates

Start date
Apr 22, 2025
Status verified
May 2026
Primary completion
Nov 30, 2029
Completion
Nov 30, 2029

Study Design

Enrollment
30 participants (estimated)

Primary Outcome Measure

Percentage of participants with Alagille syndrome (ALGS) who are treated with odevixibat and undergo biliary diversion surgery or liver transplantation. [ Time Frame: From first dose to end of study (approximately 5 years data collection) ]

Central Contacts

Locations (10)

Find similar trials in Los Angeles, CA

Related Studies